aTYR PHARMA (ATYR) Total Current Liabilities (2014 - 2026)

aTYR PHARMA (ATYR) has reported Total Current Liabilities for 13 consecutive years, with $11.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 26.62% year-over-year to $11.4 million; the trailing twelve-month figure through Jun 2026 stood at $11.4 million (down 26.62% YoY), and the FY2025 full-year result was $15.1 million, up 1.21% from the prior year.
• Total Current Liabilities declined to $11.4 million in Q2 2026 per ATYR's latest filing, from $11.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $16.4 million in Q4 2023 and bottomed at $6.3 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $12.9 million across 5 years, with a median of $13.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 130.53% in 2022, then plunged 33.14% in 2025.
• Over 5 years, Total Current Liabilities stood at $13.9 million in 2022, then increased by 18.42% to $16.4 million in 2023, then slipped by 8.83% to $15.0 million in 2024, then grew by 1.21% to $15.1 million in 2025, then fell by 24.77% to $11.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $11.4 million, $11.7 million, and $15.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.